HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCQB:RBCC) believes U.S. President Barack Obama should revisit his recent rejection of a plea from the nation’s governors to limit painkiller prescriptions considering the current epidemic of opioid addictions and overdoses sweeping America. The company is also looking into a wider range of solutions to the crisis, including the use of personalized medicines tied directly to a patient’s unique genomes.
On February 20, 2016, the National Governors Association (NGA) issued a bipartisan proposal to the president calling for restriction on the number of opioid prescriptions. According to the Centers for Disease Control, U.S. healthcare providers wrote 259 million prescriptions for painkillers in 2012, enough for every American adult to have a bottle of pills. Nearly 50 people die each day from opioid overdoses, the CDC said, in part due to this overabundance.
“RBCC is asking the president to reconsider,” said RBCC CEO Kimberly Palmer. “The NGA proposal is an admirable first step. However, a more complete, personalized medicine solution would be to use advanced genomic testing to determine a patient’s tolerance for painkillers, lessening the chance of addiction. Compounded pharmaceuticals, geared specifically to that person’s unique tolerances, could make a profound impact, much greater than simply cutting prescriptions.”
RBCC has spoken with Canadian indigenous groups about distribution of Naltrexone, a durable, long-lasting anti-addiction protocol, for use in the First Nations. The company is also examining opening low-cost, inclusive treatment centers in the U.S. after a recent major university study showed nearly 80 percent of addicts are shut out of the system.
For more information on RBCC’s initiatives, please visit www.rainbowbiocorp.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.